Alveolar epithelial fluid transport in acute lung injury: new insights.
Pulmonary oedema is a life-threatening condition that frequently leads to acute respiratory failure. From a physiological perspective, pulmonary oedema develops either because of an increase in lung vascular hydrostatic pressure or an increase in lung vascular permeability. Resolution of alveolar oedema depends on the active removal of salt and water from the distal air spaces of the lung across the distal lung epithelial barrier. Much has been learned about the molecular and cellular basis for oedema fluid reabsorption, including the role of apical ion transporters for sodium (epithelial sodium channel) and chloride (cystic fibrosis transmembrane conductance regulator), as well as the central importance of the sodium pump. The rate of fluid clearance can be upregulated by both catecholamine-dependent and -independent mechanisms. Injury to the alveolar epithelium can disrupt the integrity of the alveolar barrier or downregulate ion transport pathways, thus, reducing net alveolar fluid reabsorption and enhancing the extent of alveolar oedema. Endogenous catecholamines upregulate alveolar fluid clearance in several experimental models of acute lung injury, but this upregulation may be short term and insufficient to counterbalance alveolar flooding. There is new evidence, however, that pharmacological treatment with beta2-adrenergic agonists and/or epithelial growth factors may influence a more sustained stimulation of alveolar fluid reabsorption and in turn facilitate recovery from experimental pulmonary oedema. Similar results have been achieved experimentally by gene transfer to enhance the abundance of sodium transporters in the alveolar epithelium. Clinical studies show that impaired alveolar fluid transport mechanisms contribute to the development, severity and outcome of pulmonary oedema in humans. Very recent data suggest that mechanisms that augment transepithelial sodium transport and enhance the clearance of alveolar oedema may lead to more effective prevention or treatment for some types of pulmonary oedema.
Sartori
C
C
Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94143-0130, USA.
Matthay
M A
MA
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000818:Animals; D001693:Biological Transport, Active; D002395:Catecholamines / Q000502:physiology; D015633:Extravascular Lung Water / Q000378:metabolism*; D006133:Growth Substances / Q000627:therapeutic use; D006706:Homeostasis; D006801:Humans; D011650:Pulmonary Alveoli / Q000378:metabolism*; D011654:Pulmonary Edema / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D012128:Respiratory Distress Syndrome / Q000209:etiology / Q000378:metabolism*; D020545:Respiratory Mucosa / Q000378:metabolism*; D012964:Sodium / Q000378:metabolism; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D002395:Catecholamines; D006133:Growth Substances; D012964:Sodium; D000254:Sodium-Potassium-Exchanging ATPase